

October 25, 2013

**Otsuka Pharmaceutical Factory launches a newly approved plasma substitute Voluven<sup>®</sup> 6% on October 25, 2013**

Tokyo, Japan, October 25, 2013 – Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto-shi, Tokushima, Japan; President: Ichiro Otsuka; “OPF”) launches a newly approved plasma substitute “Voluven<sup>®</sup> 6%” manufactured and distributed by Fresenius Kabi Japan (Head Office: Shinagawa-ku, Tokyo, Japan; President: Felix Faupel; “FKJ”) on October 25, 2013.

OPF and FKJ entered into an exclusive distribution agreement of Voluven<sup>®</sup> 6% (News release on May 22, 2013).

Voluven<sup>®</sup> 6% is the Japan’s first preparation containing hydroxyethyl starch (HES) with a molecular weight of 130kDa, which is a plasma substitute used to maintain adequate circulating blood volume.

The HES products have been used worldwide for about 40 years to treat the decrease of circulating plasma volume and to maintain adequate circulating plasma volume. Voluven<sup>®</sup> 6% has been developed aiming to increase safety and maintain the circulating blood volume by adjusting the molecular weight and substituent group of the molecule. Voluven<sup>®</sup> 6% was initially approved in Germany in 1999 and is currently used in clinical settings in more than 75 countries.

Voluven<sup>®</sup> 6% is a plasma substitute which is suitable for maintaining circulating blood volume. The indication for the product is the maintenance of circulating blood volume and can be used even if bleeding is not observed. According to dosage and administration, the maximum dosage is 50ml/kg. This makes it possible for Voluven<sup>®</sup> 6% to be administered in higher dosages compared to the existing HES products, which can result in reducing the usage of albumin products.

We believe that Voluven<sup>®</sup> 6% can provide another option of treatment to the patients who need the plasma substitute and that we, OPF, can more contribute to healthcare through this product. We will promote the proper usage of the Voluven<sup>®</sup> 6% by informing medical personnel of precautions of the product, etc.

OPF will utilize approximately 350 Medical Representatives, specialized in the field of clinical nutrition to further promote the distribution of the Voluven<sup>®</sup> 6% in addition to “Salinhes<sup>®</sup> fluid solution 6%” and “Hespander fluid solution” (marketing authorization holder, FKJ).

OPF strives to be the best partner in clinical nutrition worldwide by continuously providing information and products which are useful for adequate nutrition management.

## Product Information

Brand name	:	Voluven <sup>®</sup> 6%
Category	:	Plasma substitute
Packaging	:	500 mL in soft bags. 20/case.
Indications	:	Maintenance of circulating blood volume
Employees	:	Not disclosed
Dosage and administration	:	Continuous administration in a peripheral vein. The dosage should be adjusted according to the patient's condition and the maximum dosage is 50 mL/kg per day. <Precautions regarding dosage and administration> Generally, 500 mL is infused via a peripheral vein over 30 minutes for adults, and 10 mL/kg is infused via a peripheral vein over 30 minutes for children.
Storage	:	Store at room temperature
Price	:	970 JPY/bag (500 mL)
Manufactured and distributed by	:	Fresenius Kabi Japan
Comarketed by	:	Otsuka Pharmaceutical Factory, Inc. Otsuka Pharmaceutical Co., Ltd.

## Company Profile

### Fresenius Kabi Japan

Established	:	March, 2007
Capital	:	765 million yen
Representative	:	Felix Faupel, President
Head office	:	4-7-35 Kita-Shinagawa, Shinagawa-ku, Tokyo, Japan
Employees	:	Not disclosed
Scope of Business	:	Import and sale of pharmaceuticals and medical devices, for the therapy and care of chronically and critically ill patients.
URL	:	<a href="http://www.fresenius-kabi.co.jp/">http://www.fresenius-kabi.co.jp/</a>

### Otsuka Pharmaceutical Factory, Inc.

Established	:	September 1, 1921
Capital	:	80 million yen
Representative	:	Ichiro Otsuka, President
Head office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima, Japan
Employees	:	2,365 (as of March 31, 2013)
Scope of Business	:	Manufacture and sale of pharmaceutical and nutritional products
URL	:	<a href="http://www.otsukakj.jp/">http://www.otsukakj.jp/</a>